Search research articles
Contact Us
Filters
Showing results (41-50 of 220) with videos related to
Page
of 22
Sort By:
Cancer Investigation
|
August 31, 2006
Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial
John D Hainsworth, Denise A Yardley, David R Spigel, et al.
Clinical Genitourinary Cancer
|
June 8, 2007
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial
John D Hainsworth, Anthony A Meluch, David R Spigel, et al.
Clinical Lymphoma & Myeloma
|
June 16, 2009
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium
John D Hainsworth, David R Spigel, Tiffanie M Markus, et al.
Cancer Journal (Sudbury, Mass.)
|
September 29, 2011
Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium
John D Hainsworth, David R Spigel, F Anthony Greco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
Bert H O'Neil, Robert Allen, David R Spigel, et al.
Cancer
|
January 15, 2008
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network
John D Hainsworth, Elizabeth R Vazquez, David R Spigel, et al.
Thrombosis Research
|
May 23, 2018
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis
Kelvin Young, Luis Paz-Ares, Nick Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2018
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
Martin Reck, Julie Brahmer, Bryan Bennett, et al.
The Oncologist
|
August 28, 2010
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies
Howard A Burris, Jeffrey R Infante, Roxanne C Jewell, et al.
Cancer
|
March 17, 2009
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
John D Hainsworth, David R Spigel, Howard A Burris, et al.
Page
of 22
Search research articles
Search
Showing results (41-50 of 220) with videos related to
Sort By:
Page
of 22
Cancer Investigation
|
August 31, 2006
Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial
John D Hainsworth, Denise A Yardley, David R Spigel, et al.
Clinical Genitourinary Cancer
|
June 8, 2007
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial
John D Hainsworth, Anthony A Meluch, David R Spigel, et al.
Clinical Lymphoma & Myeloma
|
June 16, 2009
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium
John D Hainsworth, David R Spigel, Tiffanie M Markus, et al.
Cancer Journal (Sudbury, Mass.)
|
September 29, 2011
Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium
John D Hainsworth, David R Spigel, F Anthony Greco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
Bert H O'Neil, Robert Allen, David R Spigel, et al.
Cancer
|
January 15, 2008
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network
John D Hainsworth, Elizabeth R Vazquez, David R Spigel, et al.
Thrombosis Research
|
May 23, 2018
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis
Kelvin Young, Luis Paz-Ares, Nick Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2018
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
Martin Reck, Julie Brahmer, Bryan Bennett, et al.
The Oncologist
|
August 28, 2010
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies
Howard A Burris, Jeffrey R Infante, Roxanne C Jewell, et al.
Cancer
|
March 17, 2009
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
John D Hainsworth, David R Spigel, Howard A Burris, et al.
Page
of 22